^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    lenalidomide

    i
    Other names: CC 5013, CDC 5013, ENMD 0997, IMiD3, CDC 5013, CC-5013, CDC-501, CDC-5013, IMiD-1, IMiD-3, ENMD-0997
    Company:
    Generic mfg.
    Drug class:
    TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor
    Related drugs:
    1m
    CAC-PPCL-001: A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, Institute of Hematology & Blood Diseases Hospital, China | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    lenalidomide • bortezomib • dexamethasone
    1m
    Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone (clinicaltrials.gov)
    P3, N=11, Terminated, Alliance for Clinical Trials in Oncology
    Trial completion date • Trial termination
    |
    lenalidomide • Ninlaro (ixazomib) • dexamethasone • zoledronic acid
    1m
    Lenalidomide boosts CD1d-Vδ2 bispecific antibody-engaged Vγ9Vδ2-T cell effector functions via CD28, Notch signaling and IL-2 release. (PubMed, J Immunother Cancer)
    Our findings provide a rationale to explore the combination of CD1d-Vδ2 bsTCE and the IMiD lenalidomide in patients with CD1d-expressing hematological malignancies.
    Journal
    |
    IL2 (Interleukin 2)
    |
    lenalidomide
    1m
    A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (clinicaltrials.gov)
    P1/2, N=16, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=60 --> 16
    Enrollment closed • Enrollment change
    |
    Rituxan (rituximab) • lenalidomide • Ezharmia (valemetostat)
    1m
    AugMMent: GMMG-HD11/DSMM XXI/64007957MMY3010 (clinicaltrials.gov)
    P3, N=399, Not yet recruiting, University of Heidelberg Medical Center
    New P3 trial
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • melphalan • Tecvayli (teclistamab-cqyv)
    1m
    Frailty-stratified, randomised controlled Bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma (TI-NDMM) – the FRAIL-M study (ACTRN12619001199101)
    P1/2, N=300, Active, not recruiting, Australasian Leukaemia & Lymphoma Group | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    lenalidomide • bortezomib
    1m
    GEM21menos65: NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide (clinicaltrials.gov)
    P3, N=480, Recruiting, PETHEMA Foundation | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • bortezomib • dexamethasone • Sarclisa (isatuximab-irfc) • iberdomide (CC-220)
    2ms
    TRIlogy-7: A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned (clinicaltrials.gov)
    P3, N=1000, Not yet recruiting, Janssen Research & Development, LLC
    New P3 trial
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • ramantamig (JNJ-5322) • dexamethasone injection
    2ms
    ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma (clinicaltrials.gov)
    P2, N=160, Not yet recruiting, Massachusetts General Hospital | Initiation date: Apr 2026 --> Aug 2026
    Trial initiation date
    |
    clonoSEQ®
    |
    lenalidomide • bortezomib • Elrexfio (elranatamab-bcmm) • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    2ms
    Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myeloma. (PubMed, Blood Cancer J)
    In multivariate analysis, receiving an alkylator based induction, radiation therapy, achieving a complete response after auto-SCT, use of cyclophosphamide for stem cell mobilization and lenalidomide maintenance were independent predictors of developing SHM. Patients with MM who developed a SHM had an inferior overall survival (OS). Given the median OS for MM continues to improve, monitoring for SHM and risk mitigation strategies is crucial.
    Journal
    |
    IKZF1 (IKAROS Family Zinc Finger 1)
    |
    lenalidomide • cyclophosphamide
    2ms
    Zanubrutinib, Lenalidomide, and Rituximab Demonstrate Efficacy in Relapsed/Refractory Central Nervous System Lymphoma: A Single - Center Retrospective Study. (PubMed, Indian J Hematol Blood Transfus)
    The Zanubrutinib, Lenalidomide, and Rituximab regimen appears to have promising efficacy and acceptable safety in treating relapsed/refractory PCNSL, particularly for patients with the MCD subtype.
    Retrospective data • Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD79B (CD79b Molecule)
    |
    Rituxan (rituximab) • lenalidomide • Brukinsa (zanubrutinib)
    2ms
    The Effect of Diabetes mellitus Type2 on Mobilization and Autologous Hematopoietic Stem Cell Transplantation Outcomes. (PubMed, Indian J Hematol Blood Transfus)
    However, various factors can lead to failure in hematopoietic stem cell mobilization in some patients, including age, type of malignancy, chemotherapy regimens (such as fludarabine, Melphalan, and Lenalidomide), radiotherapy, bone marrow cellularity, and comorbidities. It is crucial to recognize that diabetes can significantly affect the outcomes of hematopoietic stem cell transplantation. Factors such as poor stem cell mobilization, prolonged engraftment times, and increased need for blood product transfusions underscore the importance of considering diabetes in HSCT candidates.
    Journal
    |
    CD34 (CD34 molecule)
    |
    lenalidomide • melphalan • fludarabine IV